Two themes stood out to us:
- Health is shifting upstream—toward prevention, personalization, and continuous optimization
- Brand and discovery are being redefined by AI-driven systems
There is so much to share that we are breaking this into two articles—part one focused on health and wellness, and part two on growth, brand, and marketing.
Health and Wellness Key Takeaways: From Episodic Care to Continuous Health
- Health is becoming continuous and measurable, and the patient is becoming an active participant: Consumers are increasingly surrounded by tools that track, interpret, and influence their physical and mental state—moving health from episodic care to ongoing management. More informed, data-equipped patients are reshaping expectations for care—creating demand for tools that bridge consumer-generated data with clinical workflows.
- Demand is moving upstream: There is growing focus on prevention and holistic health—integrating sleep, exercise, nutrition, mental health, and biomarkers. Patients want to take control earlier in their health journey.
- Data is outpacing action: While data availability is accelerating, translating it into clear, actionable insights remains a core gap—for both consumers and providers. AI is emerging as a key enabler to connect and operationalize these insights.
Session Overviews
This panel, moderated by Dr. Darshan Shah (CEO & Founder, Next Health), and comprised of Pranitha Patil (Chief Business Officer, Function Health), John Sullivan (Chief Marketing Officer, WHOOP), and Steve Martocci (CEO & Co-founder, SuppCo), mapped neatly onto a single, connected ecosystem:
- The Clinic – Next Health
- The Map – Function Health
- The Fuel – SuppCo
- The Coach – WHOOP
Ten years ago, “biohacking” was a fringe pursuit, and has become a mainstream movement of people taking proactive, personalized ownership of their health span. People are using clinics, wearables, biomarkers, and supplements to build their own health ecosystems before they need clinical intervention. Together, these four companies each building a pillar may combine to offer the clearest picture yet of Medicine 3.0 in practice.
The most important shift the panel identified isn’t technological – it’s behavioral. Patients aren’t waiting to be told anymore; they’re proactively building their own protocols. The question for our portfolio companies is whether we’re positioned to be part of this ecosystem or left outside of it.
Amydis, ALZPath, Spinogenix, and MedWatch Technologies are each operating in this space, and the session reinforced what we already believe: these capabilities don’t work in isolation. Our opportunity – and obligation – is in how they connect. The through-line for Stead Impact Ventures is clear: our four investment pillars of Early Detection/Diagnosis, Prevention, Treatment, and Care map directly onto what this panel was describing.
Watch the full video of the session here
Female Voices Shaping the Next Era of Preventative Health
Panelists: Kayla Barnes-Lentz, longevity expert; Dr. Poonam Desai, DO, CMO of Longeverity Place and Founder of her Longevity; and Dr. Rhonda Patrick, PhD, CEO and Co-founder at FoundMyFitness.
This session reinforced a central SXSW theme: preventative health is becoming personalized, data-driven, and increasingly consumer-led—shifting from reactive care to proactive optimization.
Panelists emphasized the importance of individuals taking ownership of their health through continuous monitoring of key biomarkers, including visceral fat, inflammation, VO₂ max, heart rate variability (HRV), bone density, and muscle mass. Nutrition was framed as foundational, with a focus on whole foods, adequate protein and fiber intake, and targeted supplementation (e.g., Omega-3s, Vitamin D3).
Exercise and sleep emerged as critical levers for long-term healthspan. High-intensity cardiovascular training (e.g., Norwegian 4×4 protocols) and strength training were highlighted as essential for metabolic and cognitive health, while sleep remains a primary driver of recovery and overall system performance.
The discussion also highlighted advances in women’s health, including emerging diagnostics such as “ovarian age” testing and evolving perspectives on hormone replacement therapy (HRT). Panelists noted the importance of timing and delivery methods, with increasing preference for non-oral approaches and earlier intervention around menopause.
For Stead Impact Ventures, this session reinforces a shift already reflected in or portfolio: the move toward continuous, personalized health driven by measurable biomarkers and early intervention. Importantly, the session also underscored the need to design for – and speak directly to – the female consumer.